While scientific data suggests that BTX1204 could be more effective than Crisaborole, Menlo Therapeutics just reported some 'statistically insignificant' data on their Phase 2 trial for the pruritus associated with Atopic Dermatitis:
https://globenewswire.com/news-rele...uritus-Associated-with-Atopic-Dermatitis.html
Another risk reduction for BOT as potential competitors gets wiped out.
Ann: Enrolment of BTX 1204 Atopic Dermatitis Study Completed, page-19
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $752.8M | |||
| Open | High | Low | Value | Volume |
| 41.0¢ | 43.5¢ | 41.0¢ | $2.989M | 7.071M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 408524 | 41.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 30000 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| BOT (ASX) Chart |